JLE

Néphrologie & Thérapeutique

MENU

Atypical hemolytic and uremic syndrome in Algeria: diagnostic difficulties and therapeutic constraints Volume 19, issue 6, October 2023

Figures


  • Figure 1

  • Figure 2

Tables

Authors
1 CHU Mustapha Pacha, service de néphrologie, dialyse et transplantation, 1945, place du 1er mai, Sidi M’Hamed 16000, Alger, Algérie
2 Laboratoire de biologie médicale, Établissement public hospitalier, Rouïba 16012, Alger, Algérie
3 Hôpital Nefissa Hamoud, CHU Hussein-dey, service de néphrologie pédiatrique, Unité de soins intensifs, Hussein-Dey 16005, Alger, Algérie
4 Hôpital Nefissa Hamoud, CHU Hussein-dey, service de chirurgie infantile, Hussein-Dey 16005, Alger, Algérie
5 Hôpital Nefissa Hamoud, CHU Hussein-dey, service de cardiologie, Unité de cardiologie interventionnelle, Hussein-Dey 16005, Alger, Algérie
Correspondance : S. Chelghoum
souadchelghoum399@gmail.com

Atypical Hemolytic Uremic Syndrome (aHUS) is a systemic disease due to dysregulation of the alternate complement pathway, mortality is estimated at 10% and more than 50% of patients progress to end-stage renal disease. The aim of this study was to summarize the clinical data and biological results as well as the evolution and management of patients with aHUS seen over a period of four years in one specialized department in Algeria. Our study was observational and longitudinal. The inclusion criteria were: the clinical-biological triad of aHUS and age ≤ 16 years. The type of treatment, the presence of complement mutation or anti-complement factor autoantibodies were not eligibility conditions. On inclusion and every six months, demographic data, clinical and biological history and results after treatment were collected prospectively. Our workforce consisted of 21 children with aHUS. Thirteen patients benefited from a complement study; among them, 7 had complement abnormalities. Eleven children had familial HUS; among them 8 died and 6 were less than one year old. Plasma exchanges were performed in two children. Six patients received eculizumab, with an average age of 3.6 years. After the acute phase, 9 children recovered their kidney function, one child had developed a chronic kidney disease (CKD), and 11 died, among them 8 belong to aHUS families. Fifty percent of deaths occurred in the first 3 months. At 2 years of evolution, out of 7 children having reached this stage, five had renal sequelae and four of them had CKD. The severe prognosis of this disease makes early diagnosis and treatment essential.